Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
22.64
Nov 18 • 3:59 PM ET Dollar change-3.12 Percentage change(-12.11%)
Aftermarket Close
22.31
Aftermarket • 5:00 PM ET Dollar change-0.33 Percentage change(-1.44%)
Nov 16, 4:35 PMWindward Bio closed its IPO and Sanofi private placement with full underwriter option exercise, raising about $251.2 million in gross proceeds.
Index
-
Market Cap
1.31B
Enterprise Value
1.13B
Income
-68.21M
Sales
0.00M
Book/sh
17.21
Cash/sh
3.21
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
-
IPO
Nov 13, 2026
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.32
P/C
7.05
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
8.57
Current Ratio
8.57
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-7.42
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-31.00%
Sales Q/Q
-
Earnings
-
EPS/Sales Surpr.
- -
Insider Own
-
Insider Trans
-
Inst Own
36.94%
Inst Trans
-
ROA
-
ROE
-
ROIC
-25.65%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-15.32%
SMA50
-15.32%
SMA200
-15.32%
Trades
Shs Outstand
15.44M
Shs Float
-
52W High
33.99 -33.38%
52W Low
18.35 23.38%
Volatility
- -
ATR (14)
10.68
RSI (14)
-
Beta
-
Rel Volume
0.88
Avg Volume
588.89K
Volume
518,215
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
Perf YTD
23.38%
Perf Year
-
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Recom
-
Target Price
-
Prev Close
25.76
Price
22.64
Change %
-12.11%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stampacchia OtelloDirectorNov 16 '26Buy17.001,750,00029,750,000875,000Nov 18 04:30 PM
Its lead programs target thymic stromal lymphopoietin and interleukin-13 and are in clinical development. Windward Bio Group AG is a Swiss clinical-stage biotechnology company founded in 2024 that develops ultra-long-acting monoclonal antibodies for serious respiratory and dermatologic immunological diseases, including asthma, chronic obstructive pulmonary disease, and atopic dermatitis.
CEO & Chair of the Board of DirectorsDr. Luca Santarelli M.D.
Chief Financial OfficerDr. Claudia D'Augusta Ph.D.
Chief Operating OfficerMr. Kevin Harris M.B.A.